Cross-border deals are down and investment has dried up, while geopolitical tensions have started hitting the Chinese biotech sector in unprecedented ways. Biopharma firms are expecting more rainy days ahead and are embracing new fundraising and deal-making approaches to survive and thrive.

Direct seller declines to provide guidance due to dynamic macroeconomic environment but expects a return to growth by end of year led by North America.

Survey it commissioned shows 40% of US consumers turning to “side hustles” such as selling products for MLMs. Firm also launched 106 SKUs during the January-March period and has hired former Fiat Chrysler Automobiles exec as investors relations VP.

Kochanowski retires with CHPA Career Achievement award; Haelon’s Paley chairs CHPA board; House Oversight Committee chair, FTC commissioner speak at NCPA Fly-In; NasoClenz provided to help consumers following East Palestine disaster; CRN’s Mister attends White House End Hunger launch.